| 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns | 07/02 17:05 | investorplace.com |
| Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? | 06/20 10:45 | zacks.com |
| Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) | 06/17 08:45 | newsfilecorp.com |
| Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress | 06/17 08:00 | prnewswire.com |
| Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial | 06/14 08:30 | prnewswire.com |
| Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting | 06/11 08:30 | prnewswire.com |
| Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 | 06/10 19:22 | investorplace.com |
| Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting | 06/10 08:30 | prnewswire.com |
| Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar | 06/07 07:30 | investorplace.com |
| Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity | 05/15 08:30 | prnewswire.com |